Delivery Order SPE2DB25D2203-SPE2DB25FPSDW
- Not listed
- The Defense Logistics Agency awarded a $25,044.82 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $36,113.23 on July 29, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by July 30, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) valued at $10,076.28. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $4.8K delivery order on September 4, 2025, for Myrbetriq ER 25 mg tablets (90-count) under a firm fixed price contract with a completion date of September 5, 2025. The contract was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $5,755.12. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a ceiling value of $46,869.28. This firm fixed-price delivery order, with an ultimate completion date of September 29, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Myrbetriq ER 25 mg tablets (30-count units) valued at $1,549.42. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a ceiling value of $15,833.37. This firm fixed-price contract, with an ultimate completion date of July 28, 2025, represents a non-set-aside competitive award. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) under a firm fixed-price contract with a ceiling value of $8,500.15. This non-set-aside, competitively awarded delivery order is set to conclude on September 25, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of the company's role...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a ceiling value of $17,143.18. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB25D2203Indefinite Delivery Contract
- SPE2DB25D2203-SPE2DB25FPSDWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Myrbetriq ER 25 mg tablets in a quantity of 90 units, valued at $6,148.09. This non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 5, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle that runs through December 2026 and enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs globally. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's performance under its DLA prime contract demonstrates capability across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. This delivery order reflects the company's role in supporting the Defense Health Agency and broader Department of Defense medical supply requirements through the DLA's Pharmaceutical Prime Vendor program structure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 8/4/25 |